OpportunityAnalyzer: Acromegaly and Gigantism-Opportunity Analysis and Forecast to 2018
Single User License - $7995 Site User License - $15990 Corporate User License - $23985 Publication Date - Dec 2014 Pages - 161 To know more details, email to debora@reportstack.com
Contact: debora@reportstack.com Reportstack Market Research
Summary ď ś This report estimates the 2013 sales for acromegaly and gigantism at approximately $588m across the 6MM covered in this report. The market will grow moderately at a CAGR of 3.74% during the five year forecast period, generating sales of approximately $707m at the end of 2018. Growing at a CAGR of 4.58% and generating around 68% of global sales in 2018, the US market will experience twice the rate of growth of the 5EU market. Two major trends are visible among the pipeline drugs and research and development (R&D) strategies employed by companies in this chronic disease space – a focus towards the treatment of refractory patients and the improvement of drug delivery mechanisms to increase patient convenience.
Contact: debora@reportstack.com Reportstack Market Research
Scope Overview of acromegaly and gigantism, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. Annualized acromegaly and gigantism therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for five years to 2018. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the acromegaly and gigantism therapeutics market. Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Contact: debora@reportstack.com Reportstack Market Research
Key Findings One of the main drivers of the acromegaly and gigantism market during the forecast period will be the increased use of somatostatin analogs with better administration or dosing regimens; due to the recent focus on improving patient convenience for this chronic disease area. Another strong driver will be the treatment of refractory patient segments, which will lead to an overall increase in the drug treatment rate. Greater disease awareness and management of comorbidities are two of the biggest unmet needs in this market. Variation in clinical trial methodologies have hindered direct comparison of drug efficacy rates. Trial design needs to be improved by incorporating more randomized, head-to-head, prospective studies. Contact: debora@reportstack.com Reportstack Market Research
Companies Mentioned • Novartis Ipsen Pfizer Chiasma Antisense Therapeutics Isis Camurus Roche Ambrilia Endo Aspireo Peptron Glide Pharma
Contact: debora@reportstack.com Reportstack Market Research
If you are interested...
Contact : Debora White Email: debora@reportstack.com Ph:+1-888-789-6604 http://www.reportstack.com
Contact: debora@reportstack.com Reportstack Market Research